Vrije Universiteit Amsterdam

Orexo's OX640 Nasal Epinephrine Shows Rapid Absorption in Allergic Rhinitis Study

4 months ago

• Orexo AB announced positive topline results from a clinical study of OX640, a nasal rescue medication for allergic reactions, including anaphylaxis. • The study, OX640-002, demonstrated that OX640 achieved clinically relevant epinephrine plasma levels faster than intramuscular injection. • Absorption of OX640 was significantly faster under allergic rhinitis conditions, supporting rapid onset of effect in patients with airway symptoms. • The safety profile of OX640 was consistent with epinephrine's known pharmacology, with no severe adverse events reported.

Daratumumab Plus VRd Improves Outcomes in Transplant-Ineligible Multiple Myeloma Patients

6 months ago

• The phase 3 CEPHEUS trial demonstrated that adding daratumumab to VRd significantly improved outcomes for transplant-ineligible newly diagnosed multiple myeloma patients. • The quadruplet regimen achieved a 60.9% minimal residual disease (MRD) negativity rate compared to 39.4% with VRd alone, demonstrating a significant increase in treatment depth. • Progression-free survival was also significantly improved with the daratumumab regimen, showing a 43% reduction in the risk of disease progression or death. • These results suggest that daratumumab plus VRd could become a new standard of care for transplant-ineligible multiple myeloma patients, offering improved disease control.

Study Protocol for a Randomized Controlled, Non-Inferiority Trial on Blended Depression Treatment in Europe

9 years ago

The E-COMPARED project aims to evaluate the clinical and cost-effectiveness of blended depression treatment, combining Internet-based and face-to-face cognitive behavioral therapy (CBT), compared to treatment-as-usual (TAU) across eight European countries. This pragmatic, multinational trial seeks to improve access to cost-effective depression treatments, addressing the significant societal and economic burden of depression.